Alector LLC

Adimab, LLC

Robert Pejchal

Arnon Rosenthal

Tina Schwabe

Michael Kurnellas

Anthony B Cooper

Seung-Joo Lee

Nels P Nielson

Patricia Culp

Helen Lam

Ilaria Tassi

Philip Ling Kong

Eric Brown

Maximiliano Vasquez

Laura M Walker

Eric Krauland

Monica Wai Ling Leung

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, affinity-matured, humanized antibodies, antibody fragments, etc., that specifically bind a Sortilin protein, e.g., human Sortilin or mammalian Sortilin, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

Anti-Sortilin antibodies and methods of use thereof

Anti-sortilin antibodies and methods of use thereof

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 or human TREM2, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

Anti-TREM2 antibodies and methods of use thereof

Anti-CD3 binding domains and antibodies comprising them, including multispecific antibodies, with, inter alia, desirable T-cell activation and (re)directed target cell killing potency and developability, profiles are provided, as well as methods for their identification, isolation, and generation, and methods for their preparation and use. Reagents for identifying, isolating, selecting, generating and characterizing CD3 binding domains and antibodies comprising them are also provided.

Anti-CD3-binding domains and antibodies comprising them, and methods for their generation and use

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Sortilin protein, e.g., human Sortilin or a mammalian Sortilin, and use of such compostions in preventing, reducing risk, or treating an individual in need thereof.

Methods of use of anti-Sortilin antibodies for treating a disease, disorder, or injury

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

Anti-CD33 antibodies and methods of use thereof

Methods of increasing progranulin levels using anti-Sortilin antibodies

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Sortilin protein, e.g., human Sortilin or a mammalian Sortilin, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

Isolated nucleic acids encoding anti-sortilin antibodies

Growing community of inventors

Lebanon, NH, United States of America

Robert Pejchal